AlzforumCRISPR Reveals New Suppressors of α-Synuclein ToxicityAlzforumFor targeted editing of DNA, CRISPR-Cas9 technology relies on small hairpin guide RNAs (gRNAs) that direct the Cas9 nuclease to a complementary sequence in the genome (Sep 2014 news)… Continue reading
Science Daily |
Reengineered immune system cells show early promise against HIV …
Science Daily Improving on a previous attempt, scientists have developed a new strategy that could potentially be used to reengineer a patient’s own immune system cells to … |
FierceBiotech |
Revamped CAR–T could curb HIV levels without antiretroviral drugs
FierceBiotech Adding a synthetic CAR protein to T cells makes them better able to fight a specific target, such as cancer or HIV. CAR-T therapy involves extracting a patient’s T cells, re-engineering them in a lab to express specific CAR proteins and then injecting … |
MarketWatch |
Spark Therapeutics’ promising gene therapy for vision loss could cost $1 million
MarketWatch Spark Therapeutics’ gene therapy for an otherwise incurable rare eye disease, if approved, could be a major milestone for the disease itself as well as the field of gene therapy. The therapy, Luxturna, was recommended for approval by a Food and Drug … Spark Therapeutics Inc. (ONCE) Moves Lower on Volume Spike for October 13Equities.com Spark Therapeutics (NASDAQ:ONCE): BMO Capital Reconfirms “Outperform” Rating Today, Has a Target of $101/ShareWeeklyHub 19.91 % to Target, BMO Capital Reconfirms ‘Outperform’ Rating on Spark Therapeutics (NASDAQ:ONCE) Shares TodayFinance News Daily Weekly Register all 88 news articles » |